SHSE:603087 has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SHSE:603087 has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gan and Lee Pharmaceuticals SHSE:603087
Gan and Lee Pharmaceuticals SHSE:603087 -2.27% 90 Piotroski F-Score is 6 as of Sep. 12, 2026, which is at its 10-year median of 6.00. GuruFocus rates SHSE:603087 with a GF Score™ of 90/100 and a GF Value™ of ¥73.00 (Fairly Valued). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Gan and Lee Pharmaceuticals ranks better than 80.64% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Gan and Lee Pharmaceuticals has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Gan and Lee Pharmaceuticals's Piotroski F-Score or its related term are showing as below:
During the past 13 years, the highest Piotroski F-Score of Gan and Lee Pharmaceuticals was 7. The lowest was 2. And the median was 6.
Gan and Lee Pharmaceuticals (SHSE:603087) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
The historical data trend for Gan and Lee Pharmaceuticals's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
| Gan and Lee Pharmaceuticals Annual Data | |||||||||||||||||||||
| Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | Dec25 | |||||||||||
| Piotroski F-Score | Get a 7-Day Free Trial |
|
|
3.00 | 3.00 | 7.00 | 6.00 | 7.00 | |||||||||||||
| Gan and Lee Pharmaceuticals Quarterly Data | ||||||||||||||||||||
| Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | Jun25 | Sep25 | Dec25 | Mar26 | Jun26 | |
| Piotroski F-Score | Get a 7-Day Free Trial |
|
|
|
|
|
|
|
|
|
|
|
|
6.00 | 7.00 | 7.00 | 7.00 | 6.00 | ||
For the Medical Instruments & Supplies subindustry, Gan and Lee Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Gan and Lee Pharmaceuticals's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Gan and Lee Pharmaceuticals's Piotroski F-Score falls into.
How is the Piotroski F-Score calculated?
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
| This Year (Jun26) TTM: | Last Year (Jun25) TTM: |
|
Net Income was 214.659 + 325.244 + 192.486 + 417.295 = ¥1,150 Mil. Cash Flow from Operations was 233.41 + 302.315 + 171.674 + 260.648 = ¥968 Mil. Revenue was 980.243 + 1005.108 + 878.109 + 1344.913 = ¥4,208 Mil. Gross Profit was 745.37 + 751.906 + 654.707 + 993.121 = ¥3,145 Mil. Average Total Assets from the begining of this year (Jun25) to the end of this year (Jun26) was (11877.796 + 12142.758 + 12627.043 + 12679.783 + 12762.003) / 5 = ¥12417.8766 Mil. Total Assets at the begining of this year (Jun25) was ¥11,878 Mil. Long-Term Debt & Capital Lease Obligation was ¥2 Mil. Total Current Assets was ¥5,896 Mil. Total Current Liabilities was ¥853 Mil. |
Net Income was 208.361 + 107.399 + 311.919 + 291.762 = ¥919 Mil. Revenue was 930.113 + 800.342 + 984.867 + 1081.928 = ¥3,797 Mil. Gross Profit was 725.971 + 587.077 + 755.958 + 819.961 = ¥2,889 Mil. Average Total Assets from the begining of last year (Jun24) to the end of last year (Jun25) was (11952.557 + 12221.621 + 12042.916 + 12284.435 + 11877.796) / 5 = ¥12075.865 Mil. Total Assets at the begining of last year (Jun24) was ¥11,953 Mil. Long-Term Debt & Capital Lease Obligation was ¥3 Mil. Total Current Assets was ¥3,966 Mil. Total Current Liabilities was ¥735 Mil. |
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Gan and Lee Pharmaceuticals's current Net Income (TTM) was 1,150.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Gan and Lee Pharmaceuticals's current Cash Flow from Operations (TTM) was 968.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Score 1 if it's higher, 0 if it's lower.
| ROA (This Year) | = | Net Income | / | Total Assets (Jun25) |
| = | 1149.684 | / | 11877.796 | |
| = | 0.0967927 |
| ROA (Last Year) | = | Net Income | / | Total Assets (Jun24) |
| = | 919.441 | / | 11952.557 | |
| = | 0.07692421 |
Gan and Lee Pharmaceuticals's return on assets of this year was 0.0967927. Gan and Lee Pharmaceuticals's return on assets of last year was 0.07692421.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Score 1 if CFROA > ROA, 0 if CFROA <= ROA.
Gan and Lee Pharmaceuticals's current Net Income (TTM) was 1,150. Gan and Lee Pharmaceuticals's current Cash Flow from Operations (TTM) was 968.
==> 968 <= 1,150 ==> CFROA <= ROA ==> Score 0.
Funding
Question 5. Change in Gearing or Leverage
Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.
Score 0 if this year's gearing is higher, 1 otherwise.
| Gearing (This Year: Jun26) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Jun25 to Jun26 |
| = | 2.25 | / | 12417.8766 | |
| = | 0.00018119 |
| Gearing (Last Year: Jun25) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Jun24 to Jun25 |
| = | 2.805 | / | 12075.865 | |
| = | 0.00023228 |
Gan and Lee Pharmaceuticals's gearing of this year was 0.00018119. Gan and Lee Pharmaceuticals's gearing of last year was 0.00023228.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
| Current Ratio (This Year: Jun26) | = | Total Current Assets | / | Total Current Liabilities |
| = | 5896.466 | / | 853.374 | |
| = | 6.90959181 |
| Current Ratio (Last Year: Jun25) | = | Total Current Assets | / | Total Current Liabilities |
| = | 3966.169 | / | 735.07 | |
| = | 5.39563443 |
Gan and Lee Pharmaceuticals's current ratio of this year was 6.90959181. Gan and Lee Pharmaceuticals's current ratio of last year was 5.39563443.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Gan and Lee Pharmaceuticals's number of shares in issue this year was 600.749. Gan and Lee Pharmaceuticals's number of shares in issue last year was 595.162.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
| Gross Margin (This Year: TTM) | = | Gross Profit | / | Revenue |
| = | 3145.104 | / | 4208.373 | |
| = | 0.7473444 |
| Gross Margin (Last Year: TTM) | = | Gross Profit | / | Revenue |
| = | 2888.967 | / | 3797.25 | |
| = | 0.76080506 |
Gan and Lee Pharmaceuticals's gross margin of this year was 0.7473444. Gan and Lee Pharmaceuticals's gross margin of last year was 0.76080506.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
| Asset Turnover (This Year) | = | Revenue | / | Total Assets at the Beginning of This Year (Jun25) |
| = | 4208.373 | / | 11877.796 | |
| = | 0.35430588 |
| Asset Turnover (Last Year) | = | Revenue | / | Total Assets at the Beginning of Last Year (Jun24) |
| = | 3797.25 | / | 11952.557 | |
| = | 0.31769353 |
Gan and Lee Pharmaceuticals's asset turnover of this year was 0.35430588. Gan and Lee Pharmaceuticals's asset turnover of last year was 0.31769353.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
| Piotroski F-Score | = | Que. 1 | + | Que. 2 | + | Que. 3 | + | Que. 4 | + | Que. 5 | + | Que. 6 | + | Que. 7 | + | Que. 8 | + | Que. 9 |
| = | 1 | + | 1 | + | 1 | + | 0 | + | 1 | + | 1 | + | 0 | + | 0 | + | 1 | |
| = | 6 |
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Gan and Lee Pharmaceuticals has an F-score of 6 indicating the company's financial situation is typical for a stable company.
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals stock appears to be undervalued. The current stock price of ¥66.34 is trading 9.1% below its estimated GF Value™ of ¥73.00. GuruFocus considers Gan and Lee Pharmaceuticals to be Fairly Valued.
Key valuation signals for SHSE:603087:
No single metric tells the full story. See the SHSE:603087 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.